CNN reported on Friday that the vaccine advisers of the US Food and Drug Administration (FDA) are scheduled to meet on 26 February 2021 to discuss the potential emergency authorisation of a third COVID-19 vaccine for the US, this one made by Janssen Biotech, the vaccine division of US pharmaceutical company Johnson & Johnson.
Reportedly, as with the two currently authorised COVID-19 vaccines in the US, advisers and federal agencies are meeting over a weekend to try to get the vaccines to the US public as soon as possible.
The US FDA has already considered the advanced, Phase 3 clinical trial testing data presented by Janssen and says it shows the vaccine is safe and effective.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) is made up of vaccine experts and other medical professionals, industry and consumer representatives who will consider presentations from FDA about its findings, as well as from Janssen.
They'll also hear the latest from the Centres for Disease Control and Prevention about the spread of the virus, including worrying new variants, and on the CDC's surveillance for any safety worries from the currently authorised vaccines made by Pfizer/BioNTech and Moderna, CNN added.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine